Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668226 | 0.82 | GRM4 (0.48) | LRRK2GRM4 | |
| SCHEMBL16508798 | 0.80 | GRM4 (0.46) | LRRK2GRM4GSK3BDYRK1A | |
| SCHEMBL2668296 | 0.80 | GRM4 (0.48) | LRRK2GRM4 | |
| SCHEMBL2668091 | 0.79 | GRM4 (0.55) | LRRK2GRM4 | |
| SCHEMBL2668089 | 0.79 | GRM4 (0.52) | LRRK2GRM4GSK3BDYRK1A | |
| SCHEMBL9072655 | 0.77 | GRM4 (0.55) | LRRK2GRM4GSK3B | |
| SCHEMBL2668092 | 0.76 | GRM4 (0.57) | LRRK2GRM4GSK3BDYRK1A | |
| SCHEMBL2668208 | 0.75 | GRM4 (0.57) | GRM4 | |
| SCHEMBL16494940 | 0.74 | GRM4 (0.47) | GRM4GSK3BDYRK1A | |
| SCHEMBL2660111 | 0.74 | GRM4 (0.58) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2015-01-29 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | GCKR, GCK, KHK | AXL 740/4885LRRK2 2277/4885GRM4 2714/4885 |
| US-20150031669-A1 | ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR4, FGFR3 | AXL 165/4885LRRK2 410/4885GRM4 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.